Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026

Cebranopadol is an investigational, first-in-class dual-NMR agonist in development for acute and chronic pain as well as opioid use disorderFive scientific presentations will feature preclinical and clinical data advancing understanding of cebranopadol’s abuse potential, safety and effectiveness for opioid use disorder as well as its dual-mechanism approach to pain management and addiction MONMOUTH JUNCTION, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage bio